Amid controversy over Allergan’s deal with the St. Regis Mohawk Native American Tribe, the drugmaker reached a settlement with Pfizer division InnoPharma.
Under the arrangement, InnoPharma will be free to market a generic for Allergan’s Restasis in February 2024 or earlier if undisclosed conditions are met. The company will be allowed to sell an authorized generic if it has not obtained FDA approval for its version by then.
Allergan’s patents on the drug expire Aug. 27, 2024. The impending expiration is widely seen as the drugmaker’s motivation for its deal to transfer several patents to the St. Regis tribe.